Comparative Pharmacology
Head-to-head clinical analysis: OXILAN 350 versus RENORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXILAN 350 versus RENORMAX.
OXILAN-350 vs RENORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast medium that attenuates X-rays due to its iodine content, enhancing vascular and tissue contrast during imaging. It distributes in extracellular fluid and is freely filtered by glomeruli.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
Intravenous: 0.5–2 mL/kg (350 mg I/mL) for CT imaging; maximum 200 mL total. Intra-arterial: 0.3–1.5 mL/kg per injection; maximum 200 mL per procedure.
5 mg intravenously every 12 hours
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 24 hours in severe impairment).
Terminal elimination half-life: 8-10 hours in healthy adults. Prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min). Provides basis for twice-daily dosing in normal renal function.
Renal: >90% unchanged drug within 24 hours; Biliary/fecal: <2%
Primarily renal (60-70% unchanged; 10-15% as glucuronide conjugate); biliary/fecal (5-10%); 80-85% total recovered in urine and feces within 72 hours.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent